Free Trial

Eupraxia Pharmaceuticals Q4 2024 Earnings Report

Eupraxia Pharmaceuticals logo
$3.24 -0.05 (-1.37%)
As of 04/1/2025 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eupraxia Pharmaceuticals EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.20
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Eupraxia Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eupraxia Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Eupraxia Pharmaceuticals Earnings Headlines

Elon Tax Shock?
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
Eupraxia Pharmaceuticals reports FY24 EPS (76c), consensus (63c)
See More Eupraxia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

View Eupraxia Pharmaceuticals Profile

More Earnings Resources from MarketBeat